IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic laser systems, delivery devices, and consumable instrumentation to treat vision-threatening eye diseases in ophthalmology. The company is headquartered in Mountain View, California.
| Revenue (TTM) | $52.58M |
| Gross Profit (TTM) | $18.91M |
| EBITDA | $-2.47M |
| Operating Margin | -2.75% |
| Return on Equity | -56.50% |
| Return on Assets | -5.38% |
| Revenue/Share (TTM) | $3.08 |
| Book Value | $-0.07 |
| Price-to-Book | 331.20 |
| Price-to-Sales (TTM) | 0.29 |
| EV/Revenue | 0.402 |
| EV/EBITDA | -3.61 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -0.80% |
| Shares Outstanding | $17.41M |
| Float | $5.07M |
| % Insiders | 37.07% |
| % Institutions | 18.13% |
Volatility is currently expanding
MOUNTAIN VIEW, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced the expansion of its EyeProGPO product offering to include the Company's line of EndoProbe® Handpieces.
MOUNTAIN VIEW, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming Planet MicroCap Las Vegas 2026 Conference.
IRIDEX posts a narrower year-over-year net loss per share in Q1'26 as strong glaucoma product sales and lower operating costs helped offset weakness in retina sales and supply-chain disruptions.
MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended April 4, 2026.
MOUNTAIN VIEW, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the first quarter 2026 and provide a business update after the close of trading on May 19, 2026.
MOUNTAIN VIEW, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a new partnership with EyeProGPO, an ophthalmology-focused group purchasing organization serving ophthalmology practices, ambulatory surgery centers (ASC), and hospitals across the United States.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IRIX and any ticker you trade — then tracks every position and per-strategy win rate.
